{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '7.1.4.', 'Relationship of an Adverse Event to the IMP', 'The relationship of an adverse event to the IMP is characterized as follows:', 'Term', 'Definition', 'Clarification', 'No', 'This category applies to adverse', 'The relationship of an adverse event may be', 'reasonable', 'events that, after careful', 'considered \"no reasonable possibility\" if it is clearly', 'possibility', 'consideration, are clearly due to', 'due to extraneous causes or if at least 2 of the', '(not related)', 'extraneous causes (disease,', 'following apply:', 'environment, etc) or to adverse', 'It does not follow a reasonable temporal sequence', 'events that, after careful medical', 'from the administration of the IMP.', 'consideration at the time they are', \"It could readily have been produced by the patient's\", 'evaluated, are judged to be', 'clinical state, environmental, or toxic factors, or other', 'unrelated to the IMP.', 'modes of therapy administered to the patient.', 'It does not follow a known pattern of response to the', 'IMP.', 'It does not reappear or worsen when the IMP is', 're-administered.', 'Reasonable', 'This category applies to adverse', 'The relationship of an adverse event may be', 'possibility', 'events for which, after careful', 'considered \"reasonable possibility\" if at least 2 of', '(related)', 'medical consideration at the time', 'the following apply:', 'they are evaluated, a connection', 'It follows a reasonable temporal sequence from', 'with the administration of IMP', 'administration of the IMP.', 'cannot be ruled out with certainty.', 'It cannot be reasonably explained by the known', \"characteristics of the patient's clinical state,\", 'environmental or toxic factors, or other modes of', 'therapy administered to the patient.', 'It disappears or decreases on cessation or reduction in', 'dose. There are important exceptions when an', 'adverse event does not disappear after', 'discontinuation of the IMP, yet an IMP relationship', 'clearly exists.', 'It follows a known pattern of response to the IMP.', '7.1.5.', 'Serious Adverse Events', 'An additional blood sample for the measurement of IMP concentration should be collected, if', 'possible, from each patient experiencing a serious adverse event leading to discontinuation of', 'IMP at any time during the study. If study center personnel are unable to obtain a blood sample', 'in a timely fashion, this should be discussed with the medical monitor to determine whether the', 'sample still needs to be obtained.', 'For recording of serious adverse events, the study period is defined for each patient as the time', 'period from signature of the informed consent/assent form to the end of the follow-up period, as', 'defined in Section 7.1.2. If the investigator becomes aware of serious adverse events occurring in', 'a patient after the end of the follow-up period, the serious adverse events should be reported to', 'the sponsor following the procedures described in Section 7.1.5.3.1.', '81']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '7.1.5.1.', 'Definition of a Serious Adverse Event', 'A serious adverse event is an adverse event occurring at any dose that results in any of the', 'following outcomes or actions:', 'results in death', 'is a life-threatening adverse event (ie, the patient was at risk of death at the time of', 'the event); it does not refer to an event which hypothetically might have caused death', 'if it were more severe.', 'requires inpatient hospitalization or prolongation of existing hospitalization, which', 'means that hospital inpatient admission or prolongation of hospital stay were required', 'for treatment of an adverse event, or that they occurred as a consequence of the event.', 'Hospitalizations scheduled before the patient signed the informed consent form will', 'not be considered serious adverse events, unless there was worsening of the', \"preexisting condition during the patient's participation in this study.\", 'results in persistent or significant disability/incapacity (refers to a substantial', \"disruption of one's ability to conduct normal life functions)\", 'is a congenital anomaly/birth defect', 'an important medical event that may not result in death, be life-threatening, or require', 'hospitalization, but may jeopardize the patient and may require medical intervention', 'to prevent one of the outcomes listed in this definition.', 'Examples of such events are intensive treatment in an emergency room or at home for', 'allergic bronchospasm; blood dyscrasias or convulsions that do not result in', 'hospitalization; or the development of drug dependency or drug abuse. Note: Any', 'suspected transmission of an infectious agent via a medicinal product is considered an', 'important medical event.', \"All occurrences of possible drug-induced liver injury that meet Hy's law criteria, defined as all\", 'of the below, must be reported by the investigator to the sponsor as a serious adverse event:', 'alanine aminotransferase (ALT) or aspartate aminotransferase (AST) increase of', '>3 X the upper limit of normal (ULN)', 'total bilirubin increase of >2 X ULN', 'absence of initial findings of cholestasis (ie, no substantial increase of alkaline', 'phosphatase [ALP])', 'An adverse event that does not meet any of the criteria for seriousness listed above will be', 'regarded as a nonserious adverse event.', '7.1.5.2. Expectedness', 'A serious adverse event that is not included in the adverse reaction section of the relevant', 'reference safety information (RSI) by its specificity, severity, outcome, or frequency is', 'considered an unexpected adverse event. The RSI for this study is the IB.', '82']\n\n###\n\n", "completion": "END"}